Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

200.39 +7.21 (+3.73%)
Streaming Delayed Price Updated: 3:09 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
42 43 Next >
Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually... 
Via FinancialNewsMedia
Why Humana Is Suing Biogen
Biogen continues to deal with the aftermath of allegedly paying co-pays for some Medicare patients. 
Via The Motley Fool
Analyst Ratings For Biogen
Over the past 3 months, 10 analysts have published their opinion on Biogen (NASDAQ: 
Via Benzinga
Analyst Ratings For Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the... 
Via Benzinga
Where Biogen Stands With Analysts
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following a... 
Via Benzinga
Expert Ratings For Biogen
Over the past 3 months, 7 analysts have published their opinion on Biogen (NASDAQ: 
Via Benzinga
Could Biogen's Blockbuster Hopes for Alzheimer's Disease Drug Aduhelm Be Doomed?
Aduhelm could face yet another hurdle with reports of safety issues. 
Via The Motley Fool
3 Biotech Stocks That Could Make You Richer in October and Beyond
Three Motley Fool contributors think these biotech stocks should be big winners. 
Via The Motley Fool
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
Via Benzinga
Rising Oil Prices and Yields Makes Market Navigation More Complex
Bitcoin (/BTC) topped $50,000 this morning for the first since May, but traders may be more focused on oil prices and yields. Crude oil (/CL) is continuing its rise... 
Via Benzinga
Exposures Fossil Fuels
Portfolio Review: Biogen & T. Rowe Price
Biogen reported second quarter sales declined 25% to $2.8 billion. T. Rowe Price reported strong second quarter results with revenues rising 36% to $1.9 billion. 
Via Talk Markets
Healthy Climate, Healthy Lives: Engaging Employees and Suppliers
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
See Why Perrigo Shares Are Moving Higher On Thursday
Over-the-counter drugs company Perrigo Company plc (NYSE: 
Via Benzinga
Healthy Climate, Healthy Lives: Fossil Fuel Free Operations
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Benzinga's Bulls And Bears Of The Week: Apple, Bitcoin, Disney, Microsoft And More
Benzinga has examined the prospects for many investor favorite sto... 
Via Benzinga
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
It's been about four months since Biogen, Inc. (NASDAQ:BII... 
Via Benzinga
Biogen Stock Pops, But D.C. Center Bans All — Not Just Aduhelm — Sales Reps
Biogen stock rose on a buy rating even as the Aduhelm controversy deepened. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
Thinking About Buying Stock Or Options In Tesla, Ballard Power, Bloom Energy Or Biogen?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in... 
Via Benzinga
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
SOURCE: Biogen 
Via 3BL Media
Topics Emissions Supply Chain
Exposures Supply Chain
Apple Working On iPhone Features To Detect Depression, Cognitive Decline: Report
Apple, Inc. (NASDAQ: AAPL) is reportedly nurturing serious ambitions to expand its presence in the health care sector. What Happened: Apple is working on deploying its... 
Via Benzinga
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once highflying SAVA stock has plummeted in a firestorm this year. 
Via Investor's Business Daily
Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate
Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074) for small fiber neuropathy (SFN). SFN is a disorder... 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Biogen Stock Is Sinking This Week
The U.S. launch of Alzheimer's disease drug Aduhelm is off to a sluggish start. 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.